drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T-cell therapy)
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting B7‑H3 (CD276); activation via CD3ζ/co-stimulatory signaling induces cytokine release and perforin/granzyme-mediated cytotoxicity against B7‑H3–positive glioma cells. Administered intracavitary and/or intraventricular with dose escalation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracavitary, Intraventricular
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting B7-H3 (CD276) bind B7-H3 on tumor cells, triggering CD3zeta and co-stimulatory signaling that activates T cells to release cytokines and kill targets via perforin/granzyme-mediated cytotoxicity; administered locally (intracavitary/intraventricular) for B7-H3–positive glioma.
drug_name
TX103 (anti-B7-H3 CAR-T cells)
nct_id_drug_ref
NCT06482905